TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6375891

Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment with tyrosine-adsorbed Dermatophagoides pteronyssinus antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment
Number of subjects: 0
Study: 29858421

Group type: EXPERIMENTAL
Intervention: Red LED phototherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amber LED phototherapy
Number of subjects: 0
Study: 26508309

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000mg orally once daily plus prednisone 5mg orally twice daily
Number of subjects: 2184

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 2184
Study: 25573734

Group type: EXPERIMENTAL
Intervention: Crystalloids (n = 57)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Colloids (n = 58)
Number of subjects: 115
Study: 22131224

Group type: EXPERIMENTAL
Intervention: CE1 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 50% VO2peak)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CE2 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 65% VO2peak)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CE3 (2 sets of 6 exercises at 80% 1RM followed by 30 min of cycle ergometer exercise at 80% VO2peak)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (CTL 60 min of rest)
Number of subjects: 21
Study: 20353449

Group type: EXPERIMENTAL
Intervention: Interviewer-administered Child-OIDP
Number of subjects: 177

Group type: COMPARATOR
Intervention: Self-administered Child-OIDP
Number of subjects: 177
Study: 18419350

Group type: EXPERIMENTAL
Intervention: Didanosine-stavudine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mitochondrial haplogroup J
Number of subjects: 96
Study: 15787627

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Plasma Exchange + Continuous Hemodiafiltration (PE + CHDF)
Number of subjects: 9
Study: 11936482

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments pooled
Number of subjects: 0
Study: 10086434

Group type: EXPERIMENTAL
Intervention: High-dose methadone (80 to 100 mg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Moderate-dose methadone (40 to 50 mg)
Number of subjects: 192
Study: 8665532

Group type: EXPERIMENTAL
Intervention: Cycloserine treatment (various dosages)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study: 2206016

Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 7004474

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg orally nightly for 1 week
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg rectally nightly for 1 week
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin (oral and rectal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin (oral)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Indomethacin (rectal)
Number of subjects: 13
Study: 30444191

Group type: EXPERIMENTAL
Intervention: Grid Laser Photocoagulation (LAS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RAN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination Treatment (COM)
Number of subjects: 60
Study: 29940289

Group type: EXPERIMENTAL
Intervention: High abrasive slurry with 275 ppm fluoride
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High abrasive slurry with 1250 ppm fluoride
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluoride at 275 ppm with high abrasive slurry after 7 days
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brushing frequency 1×/day with high abrasive slurry after 7 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Brushing frequency 3×/day with high abrasive slurry
Number of subjects: 96
Study: 25159038

Group type: EXPERIMENTAL
Intervention: Aneurysm recurrence volumetry with HydroSoft coils (HSC)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Aneurysm recurrence volumetry with bare platinum coils (BPC)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Visual assessment with HydroSoft coils (HSC)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Visual assessment with bare platinum coils (BPC)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Aneurysm recurrence volumetry for aneurysms smaller than the sample median
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Visual assessment for aneurysms smaller than the sample median
Number of subjects: 297
Study: 23273827

Group type: EXPERIMENTAL
Intervention: Program to promote play with plush toys during the postsurgical period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard attention without specific treatment
Number of subjects: 0
Study: 22331954

Group type: EXPERIMENTAL
Intervention: Sunitinib plus docetaxel (sunitinib 37.5 mg/d, days 2 to 15 every 3 weeks; docetaxel 75 mg/m2, day 1 every 3 weeks)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Docetaxel alone (100 mg/m2 every 3 weeks)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Sunitinib plus docetaxel
Number of subjects: 593

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 593
Study: 19951008

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dan‐shen combined with low‐molecular weight dextrose
Number of subjects: 73
Study: 16973657

Group type: EXPERIMENTAL
Intervention: Ciclosporin, Tacrolimus, or p55TNFr-Ig (anti-TNF agent)
Number of subjects: 37
Study: 15815820

Group type: EXPERIMENTAL
Intervention: BioZ monitor (impedance cardiography)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Physician assessment of CI and TFC
Number of subjects: 186
Study: 11223695

Group type: EXPERIMENTAL
Intervention: Low calcium diet (< 600 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Other patients (not on low calcium diet)
Number of subjects: 35
Study: 9393299

Group type: EXPERIMENTAL
Intervention: TUR plus BCG therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: TUR
Number of subjects: 48
Study: 7896386

Group type: EXPERIMENTAL
Intervention: Folifer and calcium tablets supplied from second trimester till delivery along with regular medical supervision and nutrition education.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (C) with no supplementation.
Number of subjects: 66
Study: 3630961

Group type: EXPERIMENTAL
Intervention: Dietary supplement of 100 g/d of mackerel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meat supplement
Number of subjects: 0
Study: 31220021

Group type: EXPERIMENTAL
Intervention: Primary tendon repair
Number of subjects: 103

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 103
Study: 28340086

Group type: EXPERIMENTAL
Intervention: Massage therapy (10 sessions with licensed massage therapists)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 104
Study: 26043884

Group type: EXPERIMENTAL
Intervention: Immediate ART for 96 weeks (ART-96W)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Deferred ART until clinical or immunological progression (ART-Def)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: ART started between 12 and 24 weeks of age
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Cumulative viral load to week 84
Number of subjects: 268
Study: 23648617

Group type: EXPERIMENTAL
Intervention: Robot-guided passive stretching and active movement training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Instructed exercise program at home (control group)
Number of subjects: 24
Study: 21040773

Group type: EXPERIMENTAL
Intervention: So-cheong-ryong-tang (SCRT)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Yeon-gyo-pae-dok-san (YPS)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: SCRT and YPS
Number of subjects: 480
Study: 19190553

Group type: EXPERIMENTAL
Intervention: 15 W laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: 25 W laser
Number of subjects: 40
Study: 17083652

Group type: EXPERIMENTAL
Intervention: 50 microg of sublingual misoprostol with vaginal placebo (n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 25 microg of vaginal misoprostol with sublingual placebo (n = 70)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 50 microg of sublingual misoprostol
Number of subjects: 140

Group type: COMPARATOR
Intervention: 25 microg of vaginal misoprostol
Number of subjects: 140
Study: 15313947

Group type: EXPERIMENTAL
Intervention: Xuezhikang 1200 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11704602

Group type: EXPERIMENTAL
Intervention: LTE(4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LTD(4)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 15
Study: 8935811

Group type: EXPERIMENTAL
Intervention: Amisulpride (630-910 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amisulpride (1100 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1589668

Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg b.i.d. for 7 days
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 278
Study: 4083099

Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 14

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 14
Study: 31048405

Group type: EXPERIMENTAL
Intervention: Intramyocellular lipid (IMCL) CH2:CH3 ratio in lipodystrophic subjects
Number of subjects: 71

Group type: COMPARATOR
Intervention: Intramyocellular lipid (IMCL) CH2:CH3 ratio in athletes
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Adjusted IMCL CH2:CH3 (CH2:CH3adj)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 71
Study: 29627512

Group type: EXPERIMENTAL
Intervention: School garden intervention (n=24)
Number of subjects: 2768

Group type: COMPARATOR
Intervention: Waitlist control group (n=22)
Number of subjects: 2768
Study: 27855341

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) - six month supervised aerobic and resistance training intervention (three days/week)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 50
Study: 24833646

Group type: EXPERIMENTAL
Intervention: Sonas intervention (14 sessions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 39
Study: 22703885

Group type: EXPERIMENTAL
Intervention: Young Citizens Program (intervention)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (received the same curriculum after the trial)
Number of subjects: 24
Study: 20424027

Group type: EXPERIMENTAL
Intervention: Retrieval practice (repeatedly recalling selected items from a previously studied list)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval practice with nocturnal sleep during the retention interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrieval practice without nocturnal sleep
Number of subjects: 0
Study: 18298357

Group type: EXPERIMENTAL
Intervention: Night splint worn with the affected ankle at plantargrade, 7 nights per week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standing on a tilt table for 30 min with the ankle at maximum dorsiflexion, 5 times per week for 4 weeks
Number of subjects: 30
Study: 15985471

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 2931
Study: 12203058

Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group H (3.45 +/- 0.07 g/kg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group M (2.59 +/- 0.07 g/kg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amino acid mixture, group L (1.72 +/- 0.06 g/kg per day)
Number of subjects: 30
Study: 10331442

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLTB-36
Number of subjects: 0
Study: 8910647

Group type: EXPERIMENTAL
Intervention: Ultrasensitive enzyme immunoassay for simultaneous detection of p24 antigen and antibody IgGs to p17 and reverse transcriptase of HIV-1
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional methods for HIV-1 antibody detection
Number of subjects: 179
Study: 8478300

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily (od)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miocamycin 600 mg twice daily (bd)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Miocamycin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dirithromycin and Miocamycin
Number of subjects: 60
Study: 3515921

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg BID (twice daily)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg QID (four times daily)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Flurbiprofen treatment (both regimens)
Number of subjects: 143
Study: 29553418

Group type: EXPERIMENTAL
Intervention: 0.2 mg preservative-free morphine
Number of subjects: 121

Group type: COMPARATOR
Intervention: 20 μg fentanyl
Number of subjects: 121
Study: 29058837

Group type: EXPERIMENTAL
Intervention: Oxycodone (Oxynorm® instant)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Tramadol (Tradonal® odis)
Number of subjects: 121
Study: 24159772

Group type: EXPERIMENTAL
Intervention: Prostatotropic drug Vitaprost along with comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comprehensive treatment including preoperative trophic and flebotonic therapy, laparoscopic surgical clipping of the internal spermatic vein, and post-operative rehabilitation without Vitaprost.
Number of subjects: 90
Study: 21873710

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 21495322

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconat 0.2% for mouthrinsing twice a day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: NaF 0.05% for mouthrinsing twice a day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 16763073

Group type: EXPERIMENTAL
Intervention: Simple PIL incorporating pictograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text-only PIL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (no PIL)
Number of subjects: 0
Study: 15037060

Group type: EXPERIMENTAL
Intervention: Chromatic and luminance contrast discrimination
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Isoluminant borders discrimination
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Simple displays
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Complex displays
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Local chromatic-contrast
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Edge integration
Number of subjects: 1
Study: 11417424

Group type: EXPERIMENTAL
Intervention: High altitude (2,000 m) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low altitude (600 m) group
Number of subjects: 20
Study: 9686089

Group type: EXPERIMENTAL
Intervention: Sufentanil group (0.2 mg.kg‐1 sufentanil added to 0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (0.5% bupivacaine 1 mg.kg‐1 and 1% lidocaine 2 mg.kg‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil group
Number of subjects: 40
Study: 8317528

Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 459

Group type: COMPARATOR
Intervention: Intact group
Number of subjects: 459
Study: 3758365

Group type: EXPERIMENTAL
Intervention: Dissection technique combined with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sampling technique
Number of subjects: 0
Study: 31560101

Group type: COMPARATOR
Intervention: Check Out (CO)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Email Counselling (EC)
Number of subjects: 167
Study: 30502990

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard vitrectomy and peeling (Control)
Number of subjects: 41
Study: 26803522

Group type: EXPERIMENTAL
Intervention: Progesterone (1mg/kg per 12h for five days)
Number of subjects: 48
Study: 25540972

Group type: EXPERIMENTAL
Intervention: Dyadic action control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual action control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 22634908

Group type: EXPERIMENTAL
Intervention: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml continuously infused at 5 ml/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group BM - bupivacaine 0.125% and morphine 0.1 mg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group BC - bupivacaine 0.125% and clonidine 5 μg/ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group MC - morphine 0.1 mg/ml and clonidine 5 μg/ml
Number of subjects: 60
Study: 20538262

Group type: EXPERIMENTAL
Intervention: Repeated exposure to multi-modal cues (picture, video, and in-vivo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer inter-session intervals (4-7 days)
Number of subjects: 0
Study: 18640686

Group type: EXPERIMENTAL
Intervention: CABG patients at 5 weeks post-surgery
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CABG patients at 5 months post-surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy subjects (HS), n = 33
Number of subjects: 61
Study: 16400501

Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Iodoform paste
Number of subjects: 136
Study: 12590622

Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study: 10230950

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g administered 30 minutes before CPB)
Number of subjects: 52
Study: 8628979

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Diclofenac 100 mg slow release
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Naproxen 750-1000 mg
Number of subjects: 5000
Study: 1892794

Group type: EXPERIMENTAL
Intervention: Androstenol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Short-chain fatty acids
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no pheromone exposure)
Number of subjects: 76
Study: 6118170

Group type: EXPERIMENTAL
Intervention: Brompheniramine (12 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbinoxamine (12 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clemastine (1 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31087200

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) every 2 weeks until disease progression or toxicity requiring study discontinuation
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 30894299

Group type: EXPERIMENTAL
Intervention: Multidomain, adaptive, computerized cognitive training for 30 minutes, 5 days/week for 7 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multidomain, adaptive, computerized cognitive training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study: 29096197

Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst (cTBS) to the left-M1 during Feedback (FB) learning condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham continuous theta-burst (cTBS) to the left-M1 during Feedback (FB) learning condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst (cTBS) to the left-M1 during paired associate (PA) learning condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham continuous theta-burst (cTBS) to the left-M1 during paired associate (PA) learning condition
Number of subjects: 0
Study: 26490494

Group type: EXPERIMENTAL
Intervention: Dutch Healthy Nutrient and Food Score (DHNaFS) - fifth quintile
Number of subjects: 4307

Group type: COMPARATOR
Intervention: Dutch Undesirable Nutrient and Food Score (DUNaFS)
Number of subjects: 4307
Study: 24395612

Group type: COMPARATOR
Intervention: Baseline ALA measurement
Number of subjects: 842

Group type: COMPARATOR
Intervention: Average of baseline and follow-up ALA measurements
Number of subjects: 842

Group type: COMPARATOR
Intervention: Baseline total long chain omega-3 FAs (EPA + DHA + DPA) measurement
Number of subjects: 842

Group type: COMPARATOR
Intervention: Average of baseline and follow-up total long chain omega-3 FAs (EPA + DHA + DPA) measurements
Number of subjects: 842
Study: 21658141

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 214

Group type: COMPARATOR
Intervention: Bupropion and Nortriptyline
Number of subjects: 214
Study: 19709993

Group type: EXPERIMENTAL
Intervention: Structured Reporting System (SRS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional free-text dictation
Number of subjects: 34
Study: 17583466

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD (200mg or 300mg)
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1028
Study: 15024939

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0